<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079170</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000355083</org_study_id>
    <secondary_id>NCI-04-C-0084</secondary_id>
    <nct_id>NCT00079170</nct_id>
    <nct_alias>NCT00076193</nct_alias>
  </id_info>
  <brief_title>Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Pilot Study to Evaluate the Influence of Garlic on the Pharmacokinetics of Docetaxel in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. It is not yet known whether garlic&#xD;
      supplements affect the ability of docetaxel to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving docetaxel together with garlic works&#xD;
      in treating patients with locally advanced or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical pharmacokinetic behavior of docetaxel with and without garlic&#xD;
           tablets in patients with locally advanced or metastatic breast cancer.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the incidence of enzyme and transporter polymorphism in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot, open-label study.&#xD;
&#xD;
      Patients receive docetaxel IV over 60 minutes on days 1, 8, and 15. Treatment repeats every&#xD;
      28 days in the absence of disease progression or unacceptable toxicity. On days 5-17 of&#xD;
      course 1, patients receive oral garlic twice daily. Patients have the option of continuing&#xD;
      garlic tablets as long as they remain on study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-12 patients will be accrued for this study within 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>garlic</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
          -  Incurable, locally advanced or metastatic disease for which therapy with docetaxel is&#xD;
             a reasonable option&#xD;
&#xD;
          -  No documentation of progressive disease while on docetaxel within the past 2 months&#xD;
&#xD;
          -  Brain and/or leptomeningeal metastases are allowed only if all of the following&#xD;
             criteria are met:&#xD;
&#xD;
               -  Asymptomatic on neurological examination, including after definitive radiotherapy&#xD;
&#xD;
               -  No corticosteroid therapy to control symptoms&#xD;
&#xD;
               -  Stable lesions&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal Status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count ≥ 1,200/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 2 times ULN (3 times ULN with liver metastases)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmias&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No known gastric emptying disorders&#xD;
&#xD;
          -  No persistent diarrhea&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No prior grade 3 or 4 allergic reaction attributed to compounds of similar biological&#xD;
             composition to garlic, docetaxel, or Tween 80&#xD;
&#xD;
          -  No other concurrent uncontrolled medical condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  Must be able to ingest oral medication&#xD;
&#xD;
          -  Lactic dehydrogenase ≤ 2 times ULN&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
               -  Trastuzumab (Herceptin®) allowed after the first course of therapy at the&#xD;
                  discretion of the primary physician&#xD;
&#xD;
          -  No concurrent pegfilgrastim&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  No concurrent megestrol during the first course of study treatment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days (or 5 half-lives) since prior investigational therapy&#xD;
&#xD;
          -  No concurrent aprepitant (Emend®)&#xD;
&#xD;
          -  No concurrent or oral tetrahydrocannabinol (Marinol®) during the first course of study&#xD;
             treatment&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or anticancer medications&#xD;
&#xD;
          -  No concurrent antiepileptic therapy&#xD;
&#xD;
          -  No concurrent immunosuppressants&#xD;
&#xD;
          -  No other concurrent herbal therapies during the first month of study participation&#xD;
&#xD;
          -  No concurrent grapefruit juice during the first month of study participation&#xD;
&#xD;
          -  No concurrent administration of the following:&#xD;
&#xD;
               -  Alprazolam&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Dofetilide&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Quinine&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Tacrolimus&#xD;
&#xD;
               -  Theophylline&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
               -  Zolpidem&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C. Cox, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Medical Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

